1 Aguilar C., Husain S., and Lortholary O. (2018) Recent advances in understanding and managing infectious diseases in solid organ transplant recipients. F1000Res, 7, f1000 Faculty Rev – 661.
2 Breuer S., Rauch M., Matthes-Martin S., Lion T. (2012) Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol. Diagn. Ther., 16, 63-77.
3 Cesaro S., Dalianis T., Hanssen Rinaldo C., Koskenvuo M., Pegoraro A., Einsele H., Cordonnier C. Hirsch H.H. (2018) ECIL-6 Group ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 73 (1) 12-21.
4 Elfadawy N., Flechner S.M., Schold J.D., Srinivas T.R., Poggio E., Fatica R., Avery R., Mossad S.B. (2014) Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin. J. Am. Soc. Nephrol. 9 (3) 553–561.
5 Westphal S.G., Lyden E.R., Langewisch E.D., Miles C.D. (2017) BK viremia surveillance and outcomes in simultaneous pancreas-kidney transplant recipients. Clin. Transplant. 31 (8) e13010.
6 Lamarche C., Orio J., Collette S., Senécal L., Hébert M.J., Renoult É., Tibbles L.A., Delisle J.S. (2016) Polyomavirus and the Transplanted Kidney. Immun. Therap. Appr. Transpl. 100 (11) 2276-2287.
7 Bowman L.J., Brueckner A.J., Doligalski C.T. (2018) The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature Transplantation. 102 (2S Suppl 1) 50-59.
8 Mallat S.G., Tanios B.Y., Itani H.S., Lotfi T., McMullan C., Gabardi S., Akl E.A., Azzi J.R. (2001) CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin. J. Am. Soc. Nephrol. 7 12 (8) 1321-1336.
9 Chemaly R.F., Hill J.A., Voigt S., Peggs K.S. (2019) In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. Antiviral Res. 163, 50-58.
10 Santeusanio A.D., Lukens B.E., Eun J. (2017) Antiviral treatment of BK virus viremia after kidney transplantation. Am. J. Health. Syst. Pharm. 74 (24) 2037-2045.
11 Khalil M.A.M., Khalil M.A.U., Tan J., Khan T.F.T. (2018) Fluoroquinolones and BK Virus Nephropathy: A Myth or a Reality. Indian J. Nephrol. 28 (4) 257-264.
12 Lebreton M., Esposito L., Mengelle C., Del Bello A., Delarche A., Dörr G., Milongo D., Marion O., Izopet J., Kamar N. (2016) A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients. J. Clin. Virol. 79, 61-67.
13 Knoll G.A., Humar A., Fergusson D., Johnston O., House A.A., Kim S.J., Ramsay T., Chassé M., Pang X., Zaltzman J., Cockfield S., Cantarovich M., Karpinski M., Lebel L., Gill J.S. (2014) Levofloxacin for BK virus prophylaxis following kidney transplantation: A randomized clinical trial. JAMA 312, 2106–2114.
14 Lee B.T., Gabardi S., Grafals M., Hofmann R.M., Akalin E., Aljanabi A., Mandelbrot D.A., Adey D.B., Heher E., Fan P.-Y., Conte S., Dyer-Ward C., Chandraker (2014) A Efficacy of levofloxacin in the treatment of BK viremia: A multicenter, double-blinded, randomized, placebo-controlled trial. Clin. J. Am. Soc. Nephrol. 9, 583–589.
15 Hirsch H.H., Randhawa P.S. (2019) BK Polyomavirus in Solid Organ Transplantation - Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant: e13528. doi: 101111/ctr13528 [Epub ahead of print].
16 Schneidewind L., Neumann T., Schmidt C.A., Krüger W. (2018) Comparison of intravenous or intravesical cidofovir in the treatment of BK polyomavirus-associated hemorrhagic cystitis following adult allogeneic stem cell transplantation-A systematic review. Transpl. Infect. Dis. 20 (4) e12914.
17 Razonable R.R. (2018) Drug-resistant cytomegalovirus: clinical implications of specific mutations. Curr. Opin. Organ. Transplant. 23 (4) 388-394.
18 Teschner S., Burst V. (2010) Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy 2 (5) 637-650.
19 Bernhoff E., Tylden G.D., Kjerpeseth L.J., Gutteberg T.J., Hirsch H.H., Rinaldo C.H. (2010) Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J. Virol. 84, 2150-2156.
20 Farasati N.A., Shapiro R., Vats A., Randhawa P. (2005) Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transpl. 79 (1) 116–118.
21 Chen X.-C., Liu T., Li J.-J., He C., Meng W.-T., Huang R. (2013) Efficacy and Safety of Leflunomide for the Treatment of BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Acta Haematol. 130, 52–56.
22 Krisl J.C., Taber D.J., Pilch N., Chavin K., Bratton C., Thomas B., McGillicuddy J., Baliga P. (2012) Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin. J. Am. Soc. Nephrol. 7 (6) 1003-1009.
23 Low J.A., Magnuson B., Tsai B., and Imperiale M.J. (2006) Identification of gangliosides GD1b and GT1b as receptors for BK virus. J. Virol. 80, 1361-1366.
24 Randhawa P., Farasati N.A., Huang Y. (2007) BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport. Antimicrob. Agents. Chemother. 51 (12) 4492-4494.
25 Nelson C.D., Carney D.W., Derdowski A., Lipovsky A., Gee G.V., O’Hara B., Williard P., DiMaio D., Sello J.K., Atwood W.J. (2013) A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. mBio 4, e00729-13.
26 Maru S., Jin G., Desai D., Amin S., Shwetank, Lauver M.D., Lukacher A.E. (2017) Inhibition of retrograde transport limits polyomavirus infection in vivo. mSphere 2, e00494-17
27 Carbone M., Rudzinski J., Bocchetta M. (2003) High throughput testing of the SV40 Large T antigen binding to cellular p53 identifies putative drugs for the treatment of SV40-related cancers. Virology 315 (2) 409-414.
28 Kumar S., Narasimhan B. (2018) Therapeutic potential of heterocyclic pyrimidine scaffolds. Chem. Cent. J. 12, 38.
29 Solomyannyi R., Slivchuk S., Smee D., Choi J., Rusanov E., Zhirnov V., Brovarets V. (2018) In vitro activity of the novel pyrimidines and their condensed derivatives against poliovirus. Current Bioactive Comp. 14 (4) 1-9.
30 Solomyannyi R.N., Shablykina O.V., Moskvina M.S., Khylia V.P., Rusanov E.B., Brovarets V.S. (2019) 8-(Methyl(phenyl)sulfonyl)-2,6-dihydroimidazo[1,2-c]-pyrimidin-5(3H)-ones and 9-(methyl¬(phenyl)¬sulfonyl)-2,3,4,7-dihydro-6H-pyrimido[1,6-a]pyrimidin-6-ones: synthesis and antiviral activity. Chem. Heterocycl. Compd. 55 (4/5) 401–407.
31 Manos-Turvey A., Al-Ashtal H.A., Needham P.G., Hartline C.B., Prichard M.N., Wipf P., Brodsky J.L. (2016) Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family members. Bioorg. Med. Chem. Lett. 26, 5087-5091.
32 Prichard M.N., Williams J.D., Komazin-Meredith G., Khan A.R., Price N.B., Jefferson G.M., Harden E.A., Hartline C.B., Peet N.P., Bowlin T.L. (2013) Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob. Agents Chemother. 57, 3518-3527.
33 Chou S., Merigan T.C. (1983) Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N. Engl. J. Med. 308 (16) 921–925.
34 Leung A.Y., Suen C.K., Lie A.K., Liang R.H., Yuen K.Y., Kwong Y.L. (2001) Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 98 (6) 1971 1978.